BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:QL2108 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of QL2108\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06884891-1467@assetmemo.bio
DTSTAMP:20261121T004020Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:QL2108: Phase 3 readout est. (NCT06884891)
DESCRIPTION:QL2108\, phase 3\, Atopic Dermatitis.\nStudy: A Phase Ⅲ Compa
 rative Study of QL2108 to Dupixent®\nEstimated primary completion: May 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ql2108#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06884891
URL:https://assetmemo.bio/drug/ql2108#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
